Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Prevalence of healthcare-associated infections in Dutch nursing homes: follow-up 2010-2017.

Eikelenboom-Boskamp A, Saris K, van Loosbroek M, Drabbe MIJ, de Jongh F, de Jong JWD, Boom-Poels PGM, Voss A.

J Hosp Infect. 2018 Aug 25. pii: S0195-6701(18)30443-2. doi: 10.1016/j.jhin.2018.08.011. [Epub ahead of print]

PMID:
30149087
2.

A neuronal mechanism underlying decision-making deficits during hyperdopaminergic states.

Verharen JPH, de Jong JW, Roelofs TJM, Huffels CFM, van Zessen R, Luijendijk MCM, Hamelink R, Willuhn I, den Ouden HEM, van der Plasse G, Adan RAH, Vanderschuren LJMJ.

Nat Commun. 2018 Feb 21;9(1):731. doi: 10.1038/s41467-018-03087-1.

3.

Nucleus Accumbens Subnuclei Regulate Motivated Behavior via Direct Inhibition and Disinhibition of VTA Dopamine Subpopulations.

Yang H, de Jong JW, Tak Y, Peck J, Bateup HS, Lammel S.

Neuron. 2018 Jan 17;97(2):434-449.e4. doi: 10.1016/j.neuron.2017.12.022. Epub 2018 Jan 4.

PMID:
29307710
4.

Enhancing excitability of dopamine neurons promotes motivational behaviour through increased action initiation.

Boekhoudt L, Wijbrans EC, Man JHK, Luijendijk MCM, de Jong JW, van der Plasse G, Vanderschuren LJMJ, Adan RAH.

Eur Neuropsychopharmacol. 2018 Jan;28(1):171-184. doi: 10.1016/j.euroneuro.2017.11.005. Epub 2017 Nov 17.

PMID:
29153928
5.

Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report.

Kalteren WS, Schreurs MWJ, Jorritsma-Smit A, Touw DJ, de Jong JW, Zweers PGMA, Reesink FE.

Br J Clin Pharmacol. 2017 Oct;83(10):2330-2332. doi: 10.1111/bcp.13338. Epub 2017 Jun 19. No abstract available.

6.

A novel approach to map induced activation of neuronal networks using chemogenetics and functional neuroimaging in rats: A proof-of-concept study on the mesocorticolimbic system.

Roelofs TJM, Verharen JPH, van Tilborg GAF, Boekhoudt L, van der Toorn A, de Jong JW, Luijendijk MCM, Otte WM, Adan RAH, Dijkhuizen RM.

Neuroimage. 2017 Aug 1;156:109-118. doi: 10.1016/j.neuroimage.2017.05.021. Epub 2017 May 11.

PMID:
28502844
7.

Does activation of midbrain dopamine neurons promote or reduce feeding?

Boekhoudt L, Roelofs TJM, de Jong JW, de Leeuw AE, Luijendijk MCM, Wolterink-Donselaar IG, van der Plasse G, Adan RAH.

Int J Obes (Lond). 2017 Jul;41(7):1131-1140. doi: 10.1038/ijo.2017.74. Epub 2017 Mar 21.

PMID:
28321131
8.

Reducing Ventral Tegmental Dopamine D2 Receptor Expression Selectively Boosts Incentive Motivation.

de Jong JW, Roelofs TJ, Mol FM, Hillen AE, Meijboom KE, Luijendijk MC, van der Eerden HA, Garner KM, Vanderschuren LJ, Adan RA.

Neuropsychopharmacology. 2015 Aug;40(9):2085-95. doi: 10.1038/npp.2015.60. Epub 2015 Mar 4.

9.

FTO knockdown in rat ventromedial hypothalamus does not affect energy balance.

van Gestel MA, Sanders LE, de Jong JW, Luijendijk MC, Adan RA.

Physiol Rep. 2014 Dec 11;2(12). pii: e12152. doi: 10.14814/phy2.12152. Print 2014 Dec 1.

10.

Combined use of the canine adenovirus-2 and DREADD-technology to activate specific neural pathways in vivo.

Boender AJ, de Jong JW, Boekhoudt L, Luijendijk MC, van der Plasse G, Adan RA.

PLoS One. 2014 Apr 15;9(4):e95392. doi: 10.1371/journal.pone.0095392. eCollection 2014.

11.

Low control over palatable food intake in rats is associated with habitual behavior and relapse vulnerability: individual differences.

de Jong JW, Meijboom KE, Vanderschuren LJ, Adan RA.

PLoS One. 2013 Sep 10;8(9):e74645. doi: 10.1371/journal.pone.0074645. eCollection 2013.

12.

Towards an animal model of food addiction.

de Jong JW, Vanderschuren LJ, Adan RA.

Obes Facts. 2012;5(2):180-95. doi: 10.1159/000338292. Epub 2012 Apr 19. Review.

13.

Ghrelin mediates anticipation to a palatable meal in rats.

Merkestein M, Brans MA, Luijendijk MC, de Jong JW, Egecioglu E, Dickson SL, Adan RA.

Obesity (Silver Spring). 2012 May;20(5):963-71. doi: 10.1038/oby.2011.389. Epub 2012 Jan 26.

14.

Neurobiology of overeating and obesity: the role of melanocortins and beyond.

Pandit R, de Jong JW, Vanderschuren LJ, Adan RA.

Eur J Pharmacol. 2011 Jun 11;660(1):28-42. doi: 10.1016/j.ejphar.2011.01.034. Epub 2011 Feb 2. Review.

PMID:
21295024
15.

DECIBEL study: Congenital cytomegalovirus infection in young children with permanent bilateral hearing impairment in the Netherlands.

Korver AM, de Vries JJ, Konings S, de Jong JW, Dekker FW, Vossen AC, Frijns JH, Oudesluys-Murphy AM; DECIBEL collaborative study group.

J Clin Virol. 2009 Dec;46 Suppl 4:S27-31. doi: 10.1016/j.jcv.2009.09.007.

PMID:
19836301
16.

Awareness of congenital cytomegalovirus among doctors in the Netherlands.

Korver AM, de Vries JJ, de Jong JW, Dekker FW, Vossen AC, Oudesluys-Murphy AM.

J Clin Virol. 2009 Dec;46 Suppl 4:S11-5. doi: 10.1016/j.jcv.2009.09.006. Epub 2009 Oct 8.

PMID:
19818680
17.

Effects of short-acting bronchodilators added to maintenance tiotropium therapy.

Kerstjens HA, Bantje TA, Luursema PB, Sinninghe Damste HE, de Jong JW, Lee A, Wijker SP, Cornelissen PJ.

Chest. 2007 Nov;132(5):1493-9. Epub 2007 Sep 21.

PMID:
17890476
18.

Metabolic and genetic regulation of cardiac energy substrate preference.

Kodde IF, van der Stok J, Smolenski RT, de Jong JW.

Comp Biochem Physiol A Mol Integr Physiol. 2007 Jan;146(1):26-39. Epub 2006 Oct 3. Review.

PMID:
17081788
19.

[The final phase of dementia in a group of nursing home patients: prevalence and characteristics].

de Jong JW, Ekkerink JL, Touma I, Koopmans RT.

Tijdschr Gerontol Geriatr. 2005 May;36(2):72-6. Dutch.

PMID:
15948572
20.

De laatste fase van dementie bij een groep verpleeghuispatiënten: prevalentie en kenmerken.

de Jong JW, Ekkerink JL, Touma I, Koopmans RT.

Tijdschr Gerontol Geriatr. 2005 Apr;36(2):80-84. Dutch.

PMID:
23203463
21.

Myocardial contraction is 5-fold more economical in ventricular than in atrial human tissue.

Narolska NA, van Loon RB, Boontje NM, Zaremba R, Penas SE, Russell J, Spiegelenberg SR, Huybregts MA, Visser FC, de Jong JW, van der Velden J, Stienen GJ.

Cardiovasc Res. 2005 Jan 1;65(1):221-9.

PMID:
15621050
22.

Myosin light chain composition in non-failing donor and end-stage failing human ventricular myocardium.

van der Velden J, Papp Z, Boontje NM, Zaremba R, de Jong JW, Janssen PM, Hasenfuss G, Stienen GJ.

Adv Exp Med Biol. 2003;538:3-15. Review.

PMID:
15098650
23.

Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism.

Bradamante S, Barenghi L, Piccinini F, Bertelli AA, De Jonge R, Beemster P, De Jong JW.

Eur J Pharmacol. 2003 Mar 28;465(1-2):115-23.

PMID:
12650840
24.

The effect of myosin light chain 2 dephosphorylation on Ca2+ -sensitivity of force is enhanced in failing human hearts.

van der Velden J, Papp Z, Boontje NM, Zaremba R, de Jong JW, Janssen PM, Hasenfuss G, Stienen GJ.

Cardiovasc Res. 2003 Feb;57(2):505-14.

PMID:
12566123
25.

Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins.

van der Velden J, Papp Z, Zaremba R, Boontje NM, de Jong JW, Owen VJ, Burton PB, Goldmann P, Jaquet K, Stienen GJ.

Cardiovasc Res. 2003 Jan;57(1):37-47.

PMID:
12504812
26.

Calcium sensitivity of force in human ventricular cardiomyocytes from donor and failing hearts.

van der Velden J, Boontje NM, Papp Z, Klein LJ, Visser FC, de Jong JW, Owen VJ, Burton PB, Stienen GJ.

Basic Res Cardiol. 2002;97 Suppl 1:I118-26.

PMID:
12479245
27.

Preconditioning of rat hearts by adenosine A1 or A3 receptor activation.

De Jonge R, Out M, Maas WJ, De Jong JW.

Eur J Pharmacol. 2002 Apr 26;441(3):165-72.

PMID:
12063088
28.
29.

Effects of calcium, inorganic phosphate, and pH on isometric force in single skinned cardiomyocytes from donor and failing human hearts.

van Der Velden J, Klein LJ, Zaremba R, Boontje NM, Huybregts MA, Stooker W, Eijsman L, de Jong JW, Visser CA, Visser FC, Stienen GJ.

Circulation. 2001 Sep 4;104(10):1140-6.

PMID:
11535570
30.

K(ATP) channel opening during ischemia: effects on myocardial noradrenaline release and ventricular arrhythmias.

Remme CA, Schumacher CA, de Jong JW, Fiolet JW, de Groot JR, Coronel R, Wilde AA.

J Cardiovasc Pharmacol. 2001 Sep;38(3):406-16.

PMID:
11486245
31.

Vagal neurostimulation in patients with coronary artery disease.

Zamotrinsky AV, Kondratiev B, de Jong JW.

Auton Neurosci. 2001 Apr 12;88(1-2):109-16.

PMID:
11474540
32.

Role of adenosine and glycogen in ischemic preconditioning of rat hearts.

de Jonge R, de Jong JW, Giacometti D, Bradamante S.

Eur J Pharmacol. 2001 Feb 23;414(1):55-62.

PMID:
11230995
33.
34.

Glycogen turnover and anaplerosis in preconditioned rat hearts.

Bradamante S, Marchesani A, Barenghi L, Paracchini L, de Jonge R, de Jong JW.

Biochim Biophys Acta. 2000 Nov 15;1502(3):363-79.

35.

Enhanced expression and activity of xanthine oxidoreductase in the failing heart.

de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, Sharma HS, Ceconi C.

J Mol Cell Cardiol. 2000 Nov;32(11):2083-9.

PMID:
11040111
36.

The role of adenosine in preconditioning.

de Jong JW, de Jonge R, Keijzer E, Bradamante S.

Pharmacol Ther. 2000 Aug-Sep;87(2-3):141-9. Review.

PMID:
11007996
37.

Does resveratrol induce pharmacological preconditioning?

Bradamante S, Piccinini F, Barenghi L, Bertelli AA, De Jonge R, Beemster P, De Jong JW.

Int J Tissue React. 2000;22(1):1-4.

PMID:
10937348
38.

Effect of protein kinase A on calcium sensitivity of force and its sarcomere length dependence in human cardiomyocytes.

van der Velden J, de Jong JW, Owen VJ, Burton PB, Stienen GJ.

Cardiovasc Res. 2000 Jun;46(3):487-95.

PMID:
10912459
39.
40.

Lytic skull lesions and symptomatic hypercalcaemia in bone marrow sarcoidosis.

Slart RM, de Jong JW, Haeck PW, Hoogenberg K.

J Intern Med. 1999 Jul;246(1):117-20. No abstract available.

41.

Purine in bronchoalveolar lavage fluid as a marker of ventilation-induced lung injury.

Verbrugge SJ, de Jong JW, Keijzer E, Vazquez de Anda G, Lachmann B.

Crit Care Med. 1999 Apr;27(4):779-83.

PMID:
10321669
42.

[Influenza A(H5N1): current status].

Heijnen ML, Dorigo-Zetsma JW, de Jong JW, Sprenger MJ.

Tijdschr Diergeneeskd. 1998 Feb 1;123(3):86-7. Dutch. No abstract available.

PMID:
9599174
43.

Cardioprotection by ischemic preconditioning. Role of adenosine and glycogen.

de Jonge R, Bradamante S, de Jong JW.

Adv Exp Med Biol. 1998;431:279-82. Review. No abstract available.

PMID:
9598075
44.

The significance of airway responsiveness in the onset and evolution of chronic obstructive pulmonary disease.

de Jong JW, Koëter GH, Postma DS.

Clin Exp Allergy. 1997 Oct;27(10):1114-9. Review. No abstract available.

PMID:
9383250
45.

Effect of acadesine on myocardial ischaemia in patients with coronary artery disease.

de Jonge R, Macleod DC, Suryapranata H, van Es GA, Friedman J, Serruys PW, de Jong JW.

Eur J Pharmacol. 1997 Oct 15;337(1):41-4.

PMID:
9389379
46.
47.
48.

Ischemic preconditioning--do we need more (pharmacological) experiments?

de Jong JW, de Jonge R.

Basic Res Cardiol. 1997;92 Suppl 2:48-50. Review. No abstract available.

PMID:
9457373
49.

Controversies in preconditioning.

de Jong JW, de Jonge R, Marchesani A, Janssen M, Bradamante S.

Cardiovasc Drugs Ther. 1997 Jan;10(6):767-73. Review.

PMID:
9110121
50.

Preconditioning in globally ischemic isolated rat hearts: effect on function and metabolic indices of myocardial damage.

Arad M, de Jong JW, de Jonge R, Huizer T, Rabinowitz B.

J Mol Cell Cardiol. 1996 Dec;28(12):2479-90.

PMID:
9004164

Supplemental Content

Loading ...
Support Center